Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 10 of 10« First...678910

Roche’s Alecensa bests Pfizer’s Xalkori in lung cancer trial

Roche Holding AG’s Alecensa halted the spread of lung cancer for a median of 15 months longer than treatment with rival Pfizer Inc.’s Xalkori with fewer side effects, according to trial results.

Read More »

Pfizer drug delays lung cancer growth longer than Astra’s Iressa: study

A targeted drug being developed by Pfizer Inc. held advanced lung cancer in check longer than AstraZeneca’s Iressa in newly diagnosed patients, but with a higher rate of side effects, according to data.

Read More »

Merck KGaA, F-star Alpha Strike Deal

Merck KGaA struck a deal worth up to €1 billion to acquire five bispecific immuno-oncology antibodies from F-star Alpha.

Read More »

Investors Sigh With Relief as bluebird bio, Celgene’s CAR-T Candidate Keeps Multiple Myeloma Patients Relapse Free

Although a lot of attention went to unexpected data by China’s Nanjing Legend Biotech, bluebird bio and Celgene had CAR-T data of their own to brag about.

Read More »

Loxo Oncology Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It

Shares of Loxo Oncology rocketed up more than 48 percent after the company unveiled data from three trials that showed treatment with larotrectinib helped nearly three-quarters of patients battling a variety of cancers.

Read More »

Lynparza slows advanced breast cancer progression

Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca’s Lynparza versus standard chemotherapy, according to a late-stage trial.

Read More »

Pfizer defeats appeals over Zoloft birth defects

Pfizer defeated an effort to revive 300+ lawsuits alleging that its antidepressant Zoloft causes cardiac birth defects in children when taken by women during early pregnancy.

Read More »

U.S. state, local government lawsuits over opioids face uphill battle

A growing number of U.S. states, counties and cities are filing lawsuits accusing drug companies of deceptively marketing opioid painkillers to downplay their addictiveness, but some lawyers say the industry’s highly regulated nature could pose a hurdle to their success.

Read More »

Stock Tanks as Endocyte Cuts 40% of Workforce, Slashes 2 Clinical Programs

Endocyte announced the cutting of 40 percent of its workforce as the company recalibrates two clinical programs, EC1169 and EC1456.

Read More »

Elated Bristol-Myers Squibb, Seattle Genetics Rewrite Agreement to Push Promising Drug Combo Into Phase III

Six months after touting positive data from a Phase I/II combination study of Opdivo and Adcetris in patients with relapsed or refractory classical Hodgkin lymphoma at the American Society of Hematology, Bristol-Myers Squibb and Seattle Genetics are plowing forward into a Phase III trial.

Read More »

Philadelphia Drugmaker Iroko Pharma Pink Slips Another 122 Employees

Nearly nine months after slashing 25 percent of the company’s workforce, Iroko Pharmaceuticals is terminating more than 100 full-time and part-time employees.

Read More »

2-Drug HIV Treatment Filed for U.S., EU Approval

ViiV Healthcare made regulatory submissions to the EMA and the U.S. FDA for a single-tablet, two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen).

Read More »

The Best Defense is a Good Quality Offense

While data help manufacturers fix plant-floor problems and trace quality issues to their source, it also can prevent recalls. Why not proactively use data to attain an end-to-end view of operations so that product quality can be ensured while reducing recalls?

Read More »

Philips in deals with U.S. hospitals on use of its gene data platform for cancer research

Dutch healthcare technology company Philips said Thursday it had reached deals with New York’s Memorial Sloan Kettering Cancer Center (MSK) and Utah-based Intermountain Healthcare for them to use its genomics platform for cancer research and treatment.

Read More »

Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients

Roche announced U.S. FDA approval of the Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Novartis drug Zykadia (ceritinib). The Ventana ALK (D5F3) Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for Zykadia.

Read More »

EU Approves Biogen’s Spinraza for SMA

Biogen Inc.’s Spinraza secured European Union approval to treat spinal muscular atrophy (SMA), a leading genetic cause of death in infants.

Read More »

Massachusetts’ Cellanyx Develops New Method to Culture Primary Prostate Cells

Things are looking bright for tiny startup biotech Cellanyx as the company has made headway on revolutionizing precision diagnostic test for prostate cancer.

Read More »

EU Approves Brineura for CLN2 Disease

The European Commission granted marketing authorization for BioMarin Pharmaceutical’s Brineura for the treatment of tripeptidyl peptidase 1 (TPP1) deficiency.

Read More »

7 Biotechs and Pharmas That Have the Potential to Double (or More)

Jon Ogg, writing for 24/7 Wall Street, looks at seven biopharma stocks that have the potential to double or more in value during 2017.

Read More »

Health Care Trends Impacting Organized Provider Groups

The white paper explores trends and market forces affecting organized provider groups (OPGs) and identifies opportunities for pharmaceutical manufacturers to partner with OPGs to develop mutually beneficial programs addressing areas of shared interest.

Read More »

Page 10 of 10« First...678910

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation